AR

Aditya Ranjan Sahu

Director Director DIN 07158501
DIN 07158501 First appointment Sep 2014 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 2014
Shareholding value β€’β€’β€’β€’ Premium profile

About Aditya Ranjan Sahu

Data last updated:

Aditya Ranjan Sahu was a Director at Next Gen Pharma India Private Limited (2014–2017) and Designated Partner at Allante Healthcare Llp (from 2016). The companies operate in Pharma.

DIN 07158501
Primary Designation Director
Industry Pharma
First Appointment 30 Sep 2014
Oldest Company Age 11 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Sep 20142004₹5.80 Cr (FY 2023)Active
Designated Partner22 Dec 20162015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Allante Healthcare Llp
Next Gen Pharma India Private Limited
Premium access

Shareholding and investment profile for Aditya Ranjan Sahu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aditya Ranjan Sahu

Aditya Ranjan Sahu was first appointed on 30 Sep 2014 as Director at Next Gen Pharma India Private Limited. The most recent appointment on record is 22 Dec 2016 at Allante Healthcare Llp.

Aditya Ranjan Sahu held 2 earlier board appointments: Next Gen Pharma India Private Limited (Director, 30 Sep 2014 to 01 Dec 2017); Allante Healthcare Llp (Designated Partner, from 22 Dec 2016).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available